Streptococcal B vaccine conjugate - Baxter International

Drug Profile

Streptococcal B vaccine conjugate - Baxter International

Latest Information Update: 12 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International; Brigham and Womens Hospital; Harvard University
  • Class Glycoconjugates; Polysaccharides; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Streptococcal infections

Most Recent Events

  • 16 Aug 2002 Preclinical trials in Streptococcal infections in USA (unspecified route)
  • 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International
  • 30 Jun 1999 North American Vaccine has been awarded a US patent covering its unique Streptococcal B vaccine conjugate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top